Skip to content
Download PDF

Alcohol-Associated Liver Disease

Chapter 353 | Part 10: Disorders of the Gastrointestinal System · Part 10 – Gastrointestinal Disorders · Chapter 353

Key Clinical Points

  1. Alcohol-associated liver diseases (ALD) comprise a spectrum from fatty liver and steatohepatitis to fibrosis and cirrhosis.
  2. Acute alcohol-associated hepatitis (AH) is an acute-on-chronic form of ALD associated with high mortality.
  3. Characteristic laboratory findings for ALD: AST/ALT ratio >1, with serum AST rarely exceeding 300 IU/L.
  4. Severe AH is defined by a Maddrey discriminant function (MDF) ≥ 32 or Model for End-Stage Liver Disease (MELD) score >20.
  5. Glucocorticoid treatment (prednisolone 40 mg/d or methylprednisolone 32 mg/d IV) is indicated for severe AH without contraindications.
  6. Contraindications for glucocorticoids include infection, sepsis, AKI, hepatorenal syndrome, and specific comorbidities (e.g., viral hepatitis, HCC, pancreatitis).
  7. Fibrosis-4 (Fib-4) score <3.25 can be used to exclude advanced fibrosis or cirrhosis.
  8. Transient elastography (FibroScan) cutoffs: 8 kPa indicates ≥F3; >12.5 kPa indicates F4 cirrhosis.
  9. Genetic polymorphisms in PNPLA3, MBOAT7, and TM6SF2 are associated with increased risk of alcohol-associated liver cirrhosis.
  10. Alcohol abstinence is the most effective therapy to slow progression or reverse steatosis/steatohepatitis.

1. DEFINITION & OVERVIEW

• Alcohol-associated liver diseases (ALD): A spectrum of diseases associated with chronic alcohol consumption, ranging from alcohol-associated fatty liver disease and steatohepatitis to advanced liver disease including fibrosis and cirrhosis. • Acute Alcohol-Associated Hepatitis: An acute-on-chronic form of ALD associated with liver failure and high mortality. • Metabolic ALD (MetALD): A subset of patients with metabolic dysfunction–associated steatotic liver disease (MASLD) and increased alcohol consumption.

1.1 Spectrum of Disease

• Simple hepatic steatosis • Steatohepatitis • Fibrosis • Cirrhosis • Acute alcohol-associated hepatitis (acute-on-chronic form)

2. EPIDEMIOLOGY

• Prevalence of Alcohol Use: Approximately 7% of adults in the US meet criteria for "unhealthy drinking" (≥2 drinks/day for women, ≥3 drinks/day for men) or heavy episodic drinking. • Heavy Episodic Drinking: Defined as ≥4 drinks for women and ≥5 drinks for men on a single occasion. • Alcohol Units: 1 drink = ~14 g of ethanol (1 beer, 4 oz wine, or 1 oz of 80% spirits). • Impact of COVID-19: Increased excessive alcohol intake led to higher morbidity and mortality linked to ALD. • General Population Statistics: ◦ Prevalence of alcohol-associated fatty liver disease: 4.7% ◦ Prevalence of stage 2 or greater fibrosis: 1.5% • Global Impact: Liver cirrhosis is the 11th leading cause of mortality worldwide (1.16 million deaths annually). ◦ 48% of cases of cirrhosis are attributed to alcohol. • Alcohol Misuse Cohort: Among patients with alcohol misuse, 18% had fibrosis, 26% had cirrhosis, and 7% had acute AH without underlying cirrhosis. • European Incidence (Acute AH): Annual incidence is 24–27 per million in women and 46–65 per million in men.

3. ETIOLOGY & PATHOPHYSIOLOGY

• Metabolic Pathway: ◦ Ethanol is absorbed in the upper GI tract and metabolized in the liver. ◦ Metabolism 1: Alcohol dehydrogenase 1 (ADH1) converts ethanol to acetaldehyde. ◦ Metabolism 2: Cytochrome P450 family 2 subfamily E member 1 (CYP2E1), induced by chronic consumption, also converts ethanol to acetaldehyde. ◦ Toxic Effects: Acetaldehyde causes direct cellular toxicity and generates reactive oxygen species (ROS) → lipid peroxidation and DNA damage. ◦ Acetaldehyde Clearance: Acetaldehyde dehydrogenase (ALDH) oxidizes acetaldehyde into acetate. ◦ Genetic Variation: Inherited deficiency of ALDH2 (common in Asian countries) leads to acetaldehyde accumulation, causing nausea and cutaneous flushing. • Lipid Accumulation: ◦ Acetate → acetyl-coenzyme A (CoA) → fatty acid and triglyceride synthesis. ◦ Epigenetic changes: Increase expression of lipogenesis genes; decrease expression of fatty acid transport and oxidation genes. ◦ NADH/NAD+ Ratio: Increased ratio reduces mitochondrial β-oxidation. ◦ Systemic effects: Increased fatty acid mobilization from adipose tissue and the intestine → hepatic accumulation. • Fibrosis & Cirrhosis: Sustained consumption leads to fibrosis → cirrhosis → portal hypertension. • Acute Onset: Impaired liver regeneration in patients with underlying cirrhosis may contribute to the acute onset of AH. • Table 351 (Factors for Progression): ◦ Alcohol amount and duration ◦ Drinking pattern (e.g., drinking without meal, binge drinking) ◦ Genetic factors (especially PNPLA3 polymorphism) ◦ Female sex ◦ Smoking ◦ Obesity and metabolic dysfunction–associated steatotic liver disease (MASLD) ◦ Chronic liver diseases (viral hepatitis, hemochromatosis) ◦ Intestinal microbiota

3.1 Genetic Factors

• Genetics vs. Behavior: Twin studies show genetic predisposition to alcohol-associated liver cirrhosis is independent from the genetic predisposition to alcohol use disorder. • Risk Genes: ◦ PNPLA3 (patatin-like phospholipidase domain-containing 3) ◦ MBOAT7 (membrane bound O-acyltransferase domain-containing 7) ◦ TM6SF2 (transmembrane 6 superfamily member 2) • Protective Factors: HSD17B13 and FAF2 are associated with a reduced risk of developing ALD.

3.2 Gut Microbiome

• Mechanism: Alcohol use disorder → changes in gut microbiome and increased intestinal permeability. ◦ Result: Passage of bacterial lipopolysaccharide (LPS) through the portal vein into the liver. ◦ Consequence: Hepatic inflammation, hepatocyte death, and activation of fibrotic pathways.

4. CLINICAL FEATURES

• Presentation: Steatosis, steatohepatitis, and cirrhosis are often clinically silent until decompensation or acute AH occurs. • Acute AH Presentation: Patients typically have a history of heavy drinking (>40 g/d for women; >50–60 g/d for men) for >6 months with serum AST <300 IU/L. Often accompanied by fever, malaise, tender hepatomegaly, and signs of decompensation (ascites, infection, variceal bleeding, encephalopathy). • Systemic Involvement: SIRS and AKI (secondary to hepatorenal syndrome) are common. • Infection Rate: 12–26% of patients with severe AH have infections at the time of admission. • Table 352 (Symptoms and Signs): ◦ Tiredness, Malnutrition, Sarcopenia ◦ Abdomen: discomfort, hepatomegaly, splenomegaly, caput medusae, ascites, pain, shortness of breath ◦ Skin: spider angioma, palmar erythema, jaundice, ecchymoses ◦ Eyes: icteric sclerae ◦ Hands: Dupuytren contracture ◦ Extremities: edema ◦ Face: rhinophyma ◦ Reproductive: gynecomastia, gonadal atrophy, loss of libido, amenorrhea ◦ Neurologic: peripheral neuropathy, alcohol withdrawal (tachycardia, agitation, tremor, seizures, delirium), hepatic encephalopathy (asterixis, forgetfulness, altered consciousness, coma), Wernicke-Korsakoff syndrome.

5. DIFFERENTIAL DIAGNOSIS

• Requirement: Diagnosis of ALD requires exclusion of other liver diseases in heavy drinkers. • Confounding Factors (Rule out before confirming AH): ◦ Ischemic hepatitis (e.g., hypotension, massive GI bleed, cocaine use, septic shock) ◦ Drug-induced liver injury (DILI) ◦ Autoimmune liver disease ◦ Uncertain alcohol use assessment ◦ Atypical laboratory tests (AST 400 IU/L, AST/ALT ratio <1.5) • Synergistic Effects: Viral hepatitis and hemochromatosis can have synergistic effects on ALD.

6. INVESTIGATIONS & DIAGNOSIS

  1. Initial Assessment: • Simple steatosis: Often presents with normal liver function tests. • Steatohepatitis: Characterized by elevated AST and GGT.
  2. Laboratory Profiling: • General ALD: AST/ALT ratio >1; serum AST rarely >300 IU/L. • Cirrhosis markers: Elevated bilirubin, INR, low albumin, and low platelet count. • Acute AH specific: AST and ALT elevations not exceeding 400 IU/L, with AST/ALT ratio >1.5 and serum bilirubin >3 mg/dL.
  3. Screening & Quantification: • AUDIT tool for identifying patients with alcohol use disorder. • Imaging: Ultrasound, MRI, or CT to diagnose steatosis. • Noninvasive quantification: Controlled attenuation parameter (CAP) or MR-PDFF.
  4. Fibrosis Assessment: • FibroScan (Transient Elastography): ◦ 8 kPa → indicates ≥F3 advanced fibrosis ◦ >12.5 kPa → indicates F4 cirrhosis • Fib-4 Score: Serum marker (age, AST, ALT, platelets). ◦ <3.25 → excludes advanced fibrosis or cirrhosis.
  5. Histology: • Steatosis: Macrovesicular steatosis in zone 3. • Steatohepatitis: Hepatocyte injury and ballooning with Mallory-Denk bodies, necrosis, and lobular inflammation (mononuclear/neutrophilic).
  6. Rule Out Other Causes: • Rule out biliary obstruction, HCC (via imaging), viral hepatitis, Wilson's disease, and severe autoimmune liver disease. • Routine infection screening: Chest x-ray, blood, urine, and ascites cultures.

6.1 Diagnostic Scores and Cutoffs

• Maddrey Discriminant Function (MDF): 4.6 imes (prothrombin time prolongation above control in seconds) + serum bilirubin (mg/dL). • Model for End-Stage Liver Disease (MELD): Or sodium-MELD. • Age-bilirubin-INR-creatinine (ABIC) score. • Fibrosis-4 (Fib-4) score: Threshold <3.25 to exclude advanced fibrosis.

7. MANAGEMENT & TREATMENT

  1. Primary Intervention: • Prolonged alcohol abstinence (most effective for halting progression and reversing steatosis/steatohepatitis).
  2. Supportive Care (Moderate AH): • Multidisciplinary team: Alcohol use disorder specialist, dietitian, hepatologist. • Nutrition: Enteral nutrition (35–40 kcal/kg) + micronutrients (zinc) + vitamins (B and K). • Volume expansion: Intravenous albumin preferred.
  3. Pharmacologic Therapy (Severe AH): • Criteria: MDF ≥ 32 or MELD > 20, without contraindications. • Prednisolone: 40 mg/d oral for 28 days total. • Methylprednisolone: 32 mg/d IV (if unable to take oral meds) for 28 days total. • Monitoring: Lille score at 7 days. ◦ <0.45 → Responder → Continue Prednisolone. ◦ ≥0.45 → Non-responder → Stop Prednisolone.
  4. Advanced Management: • Cirrhosis: Upper GI endoscopy for varices; HCC screening (ultrasound + alpha-fetoprotein) every 6 months. • Transplantation: Liver transplantation (LT) is the leading indication in the US for alcohol-associated decompensated cirrhosis or HCC.
  5. Contraindications for Glucocorticoids: • Infection, sepsis, AKI, hepatorenal syndrome, uncontrolled GI bleeding, multiorgan failure, shock. • Concomitant diseases: Viral hepatitis, HCC, pancreatitis, DILI, active TB, and HIV.

7.1 Pharmacologic Therapy

• Prednisolone: 40 mg/d oral; 28 days total. • Methylprednisolone: 32 mg/d IV (if unable to take oral); 28 days total. • Monitoring: Lille score at 7 days.

7.2 Nutritional Support

• Enteral nutrition: Goal of 35–40 kcal/kg. • Micronutrients: Zinc supplementation. • Vitamins: Vitamin B and K supplementation.

8. PROGNOSIS & COMPLICATIONS

• Risk Factors for Decompensation: Patients with cirrhosis and ongoing alcohol use are at risk for encephalopathy, ascites, variceal bleeding, hepatorenal syndrome, and HCC. • Mortality Prediction (Short-term): ◦ Moderate AH: 20% risk of 1-year mortality. ◦ Severe AH: ~30% mortality at 3 months. ◦ Tools: Maddrey discriminant function (MDF), MELD score, or ABIC score.

8.1 Mortality Predictors

• Maddrey discriminant function (MDF) • Model for End-Stage Liver Disease (MELD) • Age-bilirubin-INR-creatinine (ABIC) score

9. SPECIAL CONSIDERATIONS

• Confounding Factors: If present, transjugural (TJ) liver biopsy is recommended to confirm diagnosis of AH. • Ischemic hepatitis • Drug-induced liver injury (DILI) • Autoimmune liver disease • Uncertain alcohol use assessment • Atypical laboratory tests (AST 400 IU/L, AST/ALT ratio <1.5) • Infection Screening: Routine chest x-ray and blood, urine, and ascites cultures are required for patients with AH.

10. KEY PEARLS & CLINICAL TRAPS

• Prevalence Trap: Only 10–20% of individuals with daily alcohol consumption/heavy drinking develop progressive liver disease. • Gender Difference: Women develop ALD at a lower daily alcohol intake. • Co-factors: Cigarette smoking is an independent risk factor for alcohol-associated cirrhosis. • Drinking Patterns: Binge drinking and excessive drinking outside meals increase risk of progression. • Metabolic Interaction: Obesity and MASLD are frequent cofactors; MetALD describes the overlap of MASL and increased alcohol consumption.

11. WHAT TO LOOK FOR — DIAGNOSTIC CLUES

• Histology: Hepatocyte injury, ballooning with Mallory-Denk bodies, necrosis, lobular inflammation (mononuclear/neutrophilic). • Fibrosis Markers: FibroScan >8 kPa (≥F3); >12.5 kPa (F4). Fib-4 <3.25 excludes advanced fibrosis. • Acute AH Profile: AST/ALT ratio >1.5, serum bilirubin >3 mg/dL, and rapid onset of jaundice with fever/malaise. • Infection Prevalence: 12–26% of severe AH patients have infections at admission.

12. WHAT EXCLUDES THE DIAGNOSIS

• Exclusionary Criteria: Diagnosis requires ruling out ischemic hepatitis, DILI, autoimmune liver disease, and other concurrent conditions (viral hepatitis, hemochromatosis). • Contraindication Check: Glucocorticoids cannot be used if infection, sepsis, AKI, hepatorenal syndrome, or uncontrolled bleeding are present.

FLOWCHARTS & ALGORITHMS

Treatment algorithm for alcohol-associated hepatitis

1. Initial Assessment: • Clinical diagnosis of AH. • Decision Point: Confounding factors? • Yes → Perform transjugural (TJ) liver biopsy to rule out other causes. • No → Proceed to Severity Stratification. 2. Severity Stratification: • Moderate AH: MDF <32 OR MELD ≤ 20 → Action: Alcohol abstinence & Nutritional support. • Severe AH: MDF ≥ 32 OR MELD > 20 → Proceed to Treatment Eligibility. 3. Treatment Eligibility (for Severe AH): • Decision Point: Contraindications for corticosteroids? • Yes → Evaluation for Liver Transplantation (LT) or supportive/palliative care. • No → Proceed to Steroid Therapy. 4. Steroid Therapy & Monitoring: • Treatment: Prednisolone 40 mg/d oral OR Methylprednisolone 32 mg/d IV (if unable to take oral). • Timeframe: 7 days. • Decision Point: Lille score? • < 0.45 (Responder) → Continue Prednisolone for 28 days total. • ≥ 0.45 (Non-responder) → Stop Prednisolone → Evaluation for Liver Transplantation (LT) or supportive/palliative care.

Reference Tables

TABLE 353-2 Symptoms and Signs Associated with Alcohol-Associated Cirrhosis and Alcohol-Associated Hepatitis •…

Harrison's 22e, p.2698

  • • Tiredness
    • Malnutrition and sarcopenia
    • Abdomen: abdominal discomfort, hepatomegaly, splenomegaly, caput
    medusae, ascites with weight gain, abdominal pain, and shortness of breath
    • Skin: spider angioma, palmar erythema, jaundice, ecchymoses
    • Eyes: icteric sclerae
    • Hands: Dupuytren contracture
    • Extremities: edema
    • Face: rhinophyma
    • Reproductive system: gynecomastia, gonadal atrophy, loss of libido,
    amenorrhea
    • Neurologic:
    • Peripheral neuropathy
    • Alcohol withdrawal: tachycardia, agitation, tremor, seizures, delirium
    • Hepatic encephalopathy: asterixis (flapping tremor), forgetfulness,
    inversion of sleep/wake pattern, altered consciousness, confusion,
    lethargy, coma
    • Wernicke-Korsakoff syndrome

TABLE 353-1 Factors for Progression of Alcohol-Associated Liver Disease • Alcohol amount and duration • Drinking…

Harrison's 22e, p.2698

  • • Alcohol amount and duration
    • Drinking pattern (drinking without meal, binge drinking)
    • Genetic factors, especially PNPLA3 polymorphism
    • Female sex
    • Smoking
    • Obesity and metabolic dysfunction–associated steatotic liver disease
    (MASLD)
    • Chronic liver diseases such as viral hepatitis and hemochromatosis
    • Intestinal microbiota